The Most Promising Monoclonal Antibodies for Long COVID

by Admin, posted in Daily Life with Long Covid, Research & Medical Insights, Support and Resources, Symptoms & Complications, Treatment and Management

Monoclonal antibodies (mAbs) have become a powerful tool in modern medicine, offering targeted treatments for everything from cancer to autoimmune diseases. But could they also hold the key to treating Long COVID? Early research suggests that some monoclonal antibodies might be effective in addressing specific subtypes of Long COVID symptoms, depending on the underlying cause.

In this article, we’ll break down what monoclonal antibodies are, which ones are showing promise for Long COVID, and how they might help people with different symptom profiles.

What Are Monoclonal Antibodies?

Monoclonal antibodies are lab-made proteins designed to mimic the immune system’s ability to fight off harmful invaders like viruses. They are engineered to target specific molecules, like a guided missile, making them a precise treatment option.

For Long COVID, the idea is to use monoclonal antibodies to tackle lingering viral fragments, inflammation, or autoimmune responses that may be causing symptoms.

Why Are Monoclonal Antibodies Relevant for Long COVID?

Long COVID appears to be a complex condition with various subtypes, including:

  1. Persistent Viral Fragments: Remnants of the SARS-CoV-2 virus might continue to trigger an immune response.
  2. Immune Dysregulation: An overactive or misfiring immune system could lead to chronic inflammation.
  3. Autoimmune Responses: The body mistakenly attacks its own tissues.
  4. Endothelial Dysfunction: Problems with blood vessels and clotting can cause fatigue, POTS (postural orthostatic tachycardia syndrome), and other issues.

By targeting specific mechanisms, monoclonal antibodies could offer relief tailored to the root cause.

Promising Monoclonal Antibodies for Long COVID

  1. EBV-Targeted mAbs
    • Why? Epstein-Barr Virus (EBV) reactivation is common in Long COVID. Studies suggest EBV may worsen symptoms like fatigue, brain fog, and immune dysregulation.
    • Example: Monoclonal antibodies like tabelecleucel (used in EBV-associated cancers) are being explored to suppress EBV reactivation.
    • Who Might Benefit? People with fatigue and brain fog linked to EBV reactivation.
  2. Anti-Interleukin-6 (IL-6) Antibodies
    • Why? IL-6 is a pro-inflammatory cytokine often elevated in Long COVID, especially in people with ongoing inflammation.
    • Example: Tocilizumab is an IL-6 blocker already used for rheumatoid arthritis and severe COVID-19 cases.
    • Who Might Benefit? Those with symptoms of systemic inflammation, such as joint pain, fever, or chronic fatigue.
  3. Anti-CCR5 Antibodies
    • Why? The CCR5 receptor plays a role in immune regulation. Blocking it could reduce inflammation and improve immune function.
    • Example: Leronlimab (investigated for HIV and COVID-19) is being studied for Long COVID.
    • Who Might Benefit? People with neuroinflammation, brain fog, or immune dysregulation.
  4. Anti-Spike Protein Antibodies
    • Why? These antibodies target lingering spike proteins from the virus, which some studies suggest may drive symptoms.
    • Example: Monoclonal antibodies like Sotrovimab or Evusheld (tixagevimab and cilgavimab) have shown promise in reducing viral persistence.
    • Who Might Benefit? People whose Long COVID symptoms began with prolonged viral illness or recurrent infections.
  5. Anti-VEGF Antibodies
    • Why? Vascular endothelial growth factor (VEGF) may contribute to blood vessel issues seen in Long COVID, including POTS and microclot formation.
    • Example: Bevacizumab is an anti-VEGF antibody used in cancer treatment but is being explored for endothelial dysfunction in Long COVID.
    • Who Might Benefit? Those with POTS, breathlessness, or fatigue due to blood vessel problems.

Monoclonal Antibodies for MCAS: Dupixent

A subset of people with Long COVID experience symptoms resembling mast cell activation syndrome (MCAS). MCAS involves overactive mast cells releasing chemicals like histamine, leading to hives, flushing, GI distress, and respiratory symptoms.

Dupixent (dupilumab) is a monoclonal antibody approved for asthma and atopic dermatitis that blocks IL-4 and IL-13, two molecules involved in allergic and immune responses. While studies on Dupixent for Long COVID are limited, it shows potential for reducing mast cell overactivity and improving symptoms like hives, allergic-type reactions, and asthma-like breathing problems.

  • Who Might Benefit? People with Long COVID experiencing MCAS-like symptoms, particularly when antihistamines and mast cell stabilizers aren’t enough.

While research is still emerging, Dupixent offers hope for managing this challenging subtype of Long COVID.

Examples of Subtypes and Matching mAbs

  1. Subtype: Viral Reactivation
    • Symptoms: Fatigue, brain fog, swollen lymph nodes.
    • Potential Treatment: EBV-targeted mAbs (e.g., tabelecleucel).
  2. Subtype: Immune Dysregulation
    • Symptoms: Fever, joint pain, fatigue.
    • Potential Treatment: Anti-IL-6 antibodies (e.g., tocilizumab).
  3. Subtype: Neuroinflammation
    • Symptoms: Brain fog, headaches, mood changes.
    • Potential Treatment: Anti-CCR5 antibodies (e.g., leronlimab).
  4. Subtype: Vascular Issues
    • Symptoms: POTS, chest pain, breathlessness.
    • Potential Treatment: Anti-VEGF antibodies (e.g., bevacizumab).
  5. Subtype: MCAS-Like Symptoms
    • Symptoms: Hives, flushing, GI issues, breathing difficulties.
    • Potential Treatment: Dupixent (dupilumab).

Challenges and Next Steps

While the potential is exciting, monoclonal antibody treatments for Long COVID are still in early stages of research. Challenges include:

  • High costs.
  • Limited availability.
  • Need for clinical trials to confirm effectiveness.

If you’re considering monoclonal antibody treatment, it’s essential to consult a doctor experienced in Long COVID and stay informed about ongoing clinical trials.

What Can You Do Now?

While monoclonal antibodies might not be widely available yet, here are some actionable steps:

  1. Track Your Symptoms: This can help identify which subtype of Long COVID you might have.
  2. Join Clinical Trials: If available in your area, consider participating in a study.
  3. Advocate for Research: Support organizations pushing for more funding and trials.

Final Thoughts

Monoclonal antibodies represent a promising frontier for Long COVID treatment, but the science is still evolving. By understanding your symptoms and staying informed, you can better navigate the options that might work for you.

For now, hope is on the horizon, and each breakthrough brings us closer to better treatments for Long COVID. If this article has been helpful, consider sharing it with someone who might benefit from learning about these exciting developments.

Disclaimer : This article is for informational purposes only and is not intended as medical advice. Please consult your healthcare provider for guidance on managing Long COVID symptoms, treatments, and health-related concerns.

Leave a comment